-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
01 Jun 2025 12:10 GMT
… AI) (anastrozole or letrozole) in combination with a … Notes
HR-positive breast cancer
Breast cancer is the second … Estrogen receptor positive breast cancers have patient specific … metastatic hormone receptor‑positive breast cancer. Breast Cancer Res. 2021; 23 …
-
Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer
01 Jun 2025 13:07 GMT
… advanced hormone receptor–positive breast cancer. Although rare at diagnosis, … AI with anastrozole or letrozole plus CDK4/6 … positive, HER2-negative advanced breast cancer is critical, because … , HER2-negative metastatic breast cancer in patients with ESR1 …
-
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
31 May 2025 18:49 GMT
… inhibitor and letrozole versus placebo … breast cancer
HR-positive breast cancer is the most prevalent type of all breast cancers … HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020 … breast cancer. Presented at San Antonio Breast Cancer Symposium …
-
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
31 May 2025 12:30 GMT
… 47;6i and letrozole versus placebo plus … breast cancer
HR-positive breast cancer is the most prevalent type of all breast cancers … in Breast Cancer
Genentech has been advancing breast cancer research … breast cancers. As our understanding of breast cancer …
-
EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
26 May 2025 06:40 GMT
… locally advanced or metastatic breast cancer in various combinations:
… 6 inhibitor and letrozole versus placebo plus … sensitive breast cancer (INAVO123; NCT06790693).
HR-positive breast cancer is … the most prevalent type of all breast cancers …
-
The Follicular Output Rate was Improved with 3-Day Letrozole Administration Compared with 5-Day Letrozole Administration Under Progestin-Primed Ovarian Stimulation
26 May 2025 23:49 GMT
… two groups.
Abbreviations: LE, letrozole; MPA, medroxyprogesterone acetate; Gn, … generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. … letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer …
-
Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer
16 May 2025 22:45 GMT
… with entrectinib plus letrozole with or without … lobular breast cancer comprises approximately 15% of all breast cancer cases … 90% of invasive lobular breast tumors lack E-cadherin. … positive, HER2-negative breast cancer who underwent surgery following …
-
Naples Prognostic Score (NPS) as a Novel Prognostic Score for Stage III Breast Cancer Patients: A Real-World Retrospective Study
12 May 2025 12:12 GMT
… therapy (tamoxifen, anastrozole, letrozole), and targeted therapy (trastuzumab … of Stage III Breast Cancer Patients
This … III breast cancer. Eventually, 306 stage III breast cancer patients … breast cancer: a systematic review and meta-analysis. Breast Cancer …
-
Considerations for the Use of Abemaciclib vs Ribociclib in Breast Cancer
09 May 2025 17:50 GMT
… ;6 inhibitors to prevent breast cancer reoccurrence after treatment.2
… Endocrine therapy was either letrozole 2.5 mg per … in patients with early breast cancer. Ther Adv Med Oncol … node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. …
-
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
02 May 2025 22:56 GMT
… of the Science Summit™ on breast cancers. “Over time, [however … HER2-negative, early-stage breast cancer treatment paradigm; key clinical … -endocrine-therapy-early-breast-cancer
US FDA broadens … and letrozole co-pack for early high-risk breast cancer. FDA …
About
© 1995-2025